ADORA2A and neoplasm: Taken together, these pre-clinical and clinical studies investigating A2aR and LAG-3 demonstrate that targeting these novel ICs to enhance anti-tumour immunity is a viable strategy for boosting the efficacy of conventional PD-1 ICBs.